Trial Profile
A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (0.5 µg to 70 µg Administered With the Respimat) of BI 1744 CL in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2014
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record